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Abstract
Sirt1 is an evolutionarily conserved NAD
+ dependent deacetylase involved in a wide range of processes including cellular
differentiation, apoptosis, as well as metabolism, and aging. In this study, we investigated the role of hypothalamic Sirt1 in
energy balance. Pharmacological inhibition or siRNA mediated knock down of hypothalamic Sirt1 showed to decrease food
intake and body weight gain. Central administration of a specific melanocortin antagonist, SHU9119, reversed the anorectic
effect of hypothalamic Sirt1 inhibition, suggesting that Sirt1 regulates food intake through the central melanocortin
signaling. We also showed that fasting increases hypothalamic Sirt1 expression and decreases FoxO1 (Forkhead
transcription factor) acetylation suggesting that Sirt1 regulates the central melanocortin system in a FoxO1 dependent
manner. In addition, hypothalamic Sirt1 showed to regulate S6K signaling such that inhibition of the fasting induced Sirt1
activity results in up-regulation of the S6K pathway. Thus, this is the first study providing a novel role for the hypothalamic
Sirt1 in the regulation of food intake and body weight. Given the role of Sirt1 in several peripheral tissues and
hypothalamus, potential therapies centered on Sirt1 regulation might provide promising therapies in the treatment of
metabolic diseases including obesity.
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Introduction
Sirt1 isanevolutionarilyconserved NAD
+-dependentdeacetylase
involved in a wide range of metabolic processes in the periphery [1].
In the liver, Sirt1 deacetylates and activates the transcriptional co-
activator PGC1-alpha and the transcription factor FoxO1 to
promote gluconeogenesis [2,3]. In the adipose tissue, Sirt1 triggers
fat mobilization by inhibiting peroxisome proliferator-activated
receptor (PPAR-gamma), and in the pancreas repression of the
uncouplingprotein 2 (UCP2) bySirt1increasesinsulinsecretion[1].
Sirt1 expression as well as its activity is nutrient sensitive. For
example, in the liver, the Sirt1 protein level increases upon fasting
[3] and decreases by high fat diet [4]. Sirt1 action in the central
nervous system has been studied as well. Sirt1 has neuroprotective
effects. For example, increased nuclear NAD biosynthesis and Sirt1
activation are linked to axonal protection [5], and hippocampus
over expression of Sirt1 provides protection against neurodegener-
ation in a mouse model of Alzheimer’s disease [6]. Sirt1 showed to
be important in the regulation of stem cells to generate either
astroglial lineage or the neuronal lineage [7]. At a global scale Sirt1
target genes in the mouse brain are deregulated by aging. This
situation (at the gene expression level) can be reversed by specific
over expression of central Sirt1 [8]. Brain Sirt1 expression increases
by caloric restriction [9], and fasting was shown to increase brain
Sirt1 protein content specifically in the hypothalamus [10]. A better
understanding of hypothalamic Sirt1 action is of crucial importance
since the hypothalamus is the primary brain center that interprets
adiposity or nutrient related inputs to regulate energy homeostasis.
Specifically, the anorexigenic proopiomelanocortin (POMC) neu-
rons and the orexigenic NPY/AgRP neurons in the arcuate nucleus
(ARC) of the hypothalamus are the major regulators of feeding and
energy expenditure [11]. Although the Sirt1 expression in POMC
neurons has been reported [10], its functional role in the
hypothalamus has not been determined. Hypothalamic control of
foodintakeand bodyweightinvolvestheactionofmetabolicsensors
including the mammalian target of rapamycin (mTOR) [12] and
AMP activated kinase (AMPK) [13]. Because of its dependence on
NAD
+, Sirt1 also functions as a metabolic sensor [14]. Therefore,
we hypothesized that hypothalamic Sirt1 represents another
metabolic factor controlling food intake. Using the rat as a
physiological in vivo model we found that ablation of Sirt1 activity
or knocking-down Sirt1 gene expression at the hypothalamic level
resulted in decreased food intake and body weight gain. Blocking
the melanocortin receptors with the melanocortin antagonist
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8322SHU9119 attenuated the anorectic effect of Sirt1 inhibition. Fasting
increased hypothalamic NAD
+ levels and Sirt1 protein content.
Inhibition of hypothalamic Sirt1 activity reversed the fasting
induced decrease of FoxO1 acetylation, and resulted in increased
POMC and decreased AgRP expressions. Regulation of POMC by
Sirt1 depends on FoxO1 as shown utilizing in vivo and in vitro
approaches. We also present data showing that hypothalamic Sirt1
regulates S6K signaling. Thus, targeting central Sirt1 signaling may
show promise for the treatment of obesity and the associated
disorders.
Results
Hypothalamic Sirt1 Regulates Food Intake and Body
Weight
To study the potential role of hypothalamic Sirt1 in energy
balance we first determined its expression in the rat hypothalamus.
Immunohistochemical (IHC) staining revealed a nuclear Sirt1
expression in certain hypothalamic centers involved in energy
homeostasis, namely the ARC and paraventricular nucleus (PVN)
of the hypothalamus (Figure S1A). By immunoblotting analysis, we
also confirmed the presence of Sirt1 in the ARC, PVN, primary
neurons, and in the mouse corticotropic AtT20 cell line (Figure
S1B) (see below). As recently described for the mouse brain [10],
Sirt1 expression is present in other brain areas such as the
hippocampal formation and cortex (Figure S1C). We next wanted
to determine if modulating Sirt1 activity or its expression would
effect food intake and body weight of adult rats. To block Sirt1
enzymatic activity we used a potent Sirt1 inhibitor [15]. This
compound (EX-527) is a small, selective inhibitor of SIRT1 that
does not inhibit histone deacetylases and is specific for Sirt1 over
other sirtuin family members [16,17]. Intracerebro-ventricular
(ICV) administration of EX-527 for 24 (Figure S1D, left and
middle panels) or 48 hours (Figure 1A left and middle panels) in
Figure 1. Hypothalamic Sirt1 regulates food intake through melanocortin receptors. (A) Pharmacological inhibition of Sirt1 decreases food
intake (left) and body weight gain (middle) in fasted rats, whereas activation of Sirt1 increases food intake (right) in re-fed rats. n=8–9, per treatment,
and per group. (B) Food intake (left) and body weight gain (right) decreases by knocking down Sirt1 expression specifically in the ARC. n=6–7, per
treatment. (C) (Left) Effect of co-administration of EX527 and SHU9119 on food intake. Animals were treated the same way as in (A). Food intake was
measured overnight for a period of 16 hours. (Right) Effect of co-administration of EX527 and SHU9119 on body weight change. Same animals were
weighed one hour before dark cycle, and in the morning. n=5 per treatment. (D) Fasted rats were icv infused with DMSO (vehicle) or EX-527 as
described in (A). One hour after second icv infusion (49-hour of fasting) rats were sacrificed. Blood was collected at the time of decapitation. Plasma
T3 and T4 was determined by RIA. (DM, DMSO; EX, EX-527; SHU, SHU9119; SA3, Sirt1 Activator 3). Values are the mean6SEM. *, 0.01,p,0.05
throughout the text (unless p is stated), vs. DMSO (A, C, D) or CTRL (B) groups. #, 0.01,p,0.05 vs. EX527 group.
doi:10.1371/journal.pone.0008322.g001
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reduced body weight gain. Both the food intake and body weight
changes induced by EX527 were Sirt1 specific because both
parameters were reversed by co-administration of a Sirt1 activator
[18] (Sirt1 activator 3, or SA3) at a dose, which alone did not
change either food intake or weight gain (Figure 1A). Induction of
hypothalamic Sirt1 activity by ICV infusion of SA3 to re-fed rats
(Figure S1D, right panel) resulted in increased short-term food
intake (Figure 1A, right). To confirm the specificity of pharma-
cological Sirt1 inhibition, and to observe whether the acute
manipulation of Sirt1 activity could be recapitulated in the long-
term, we knocked down Sirt1 expression by infusing Sirt1 specific
siRNAs directly into the ARC (Figure S1F). Consequently, Sirt1
expression was knocked-down 40% at the protein level (Figure
S1E), which was confirmed by the decreased number of Sirt1
positive ARC nuclei (Figure S1F, G). Rats with diminished ARC
Sirt1 protein consumed less food (Figure 1B, left), and gained less
weight compared to the control group (Figure 1B, right).
The Effect of Hypothalamic Sirt1 on Energy Balance Is
Mediated through Melanocortin Receptors
One of the main regulators of energy homeostasis at the
hypothalamic level is the melanocortin system. If the effect of
Sirt1 on energy balance is mediated through central melanocortin
signaling, blocking melanocortin receptors should reverse the
anorexogenic outcome of Sirt1 inhibition. To test this hypothesis,
we ICV infused rats with EX-527 and the melanocortin
antagonist SHU9119. We used a dose of SHU9119 that did
not change the overnight food intake or body weight (Figure 1C).
Administration of the melanocortin antagonist together with the
Sirt1 inhibitor completely attenuated the decreased food intake or
the weight gain induced by the Sirt1 inhibitor alone (Figure 1C).
This result also shows that the effect of the Sirt1 inhibitor on food
intake was specific and was not due to nonspecific effects such as
food aversion. It has long been accepted that the thyroid
hormone is an important determinant of overall energy
consumption in humans and animals by affects uncoupling
proteins (UCP-1, UCP-2, and UCP-3) in brown adipose tissue
(BAT), muscle, and other tissues in combination with an
activation of the sympathetic nervous system to accelerate ATP
turnover [19]. The TRH peptide produced in neurons of the
PVN is released from the median eminence to stimulate the
biosynthesis and secretion of thyroid stimulating hormone (TSH)
from the pituitary, which in turn, stimulates the biosynthesis of
thyroid hormone, thyroxine (T4), and it modified product
triidothyronine (T3) [22]. We had previously showed that the
a-MSH peptide derived from POMC processing is one of the
main regulators of the hypothalamic-pituitary-thyroid (HPT) axis
[21,20] by up-regulating the TRH neuron in the PVN. Since the
inhibition of hypothalamic Sirt1 induced an anorectic effect in a
SHU9119 dependent manner, we measured the T3 and T4
plasma levels of EX527 infused animals. As shown in Figure 1D,
inhibition of hypothalamic Sirt1 resulted in a significant rise in
plasma T3 and T4 levels, strongly suggesting that the melano-
cortin system was positively activated when Sirt1 activity was
inhibited.
Sirt1 Regulates Melanocortin System at the Level of ARC
It has been recently shown in mice that hypothalamic Sirt1
protein levels are increased by fasting [10]. We confirmed this
finding in the rat hypothalamic nuclear extracts (Figure 2A). The
fasting induced increase in hypothalamic Sirt1 protein level was
probably due to post-transcriptional regulations, because Sirt1
mRNA level was unaltered by fasting (data not shown). In
addition, as depicted in Figure 2B fasting increased ARC NAD
+
levels and the NAD
+/NADH ratio. Higher NAD
+ levels, in
addition to an elevated hypothalamic Sirt1 protein expression,
suggest that Sirt1 deacetylase activity increases upon fasting.
POMC (Figure S2A) and AgRP neurons together with the
melanocortin receptors constitute the hypothalamic part of the
central melanocortin system [23] important in the regulation of
food intake and energy expenditure. Upon fasting POMC gene
expression decreases whereas AgRP increases. Figure S2B shows
that Sirt1 is expressed virtually in all POMC neurons in the ARC,
in agreement with a previous report [10]. Since hypothalamic
Sirt1 regulates food intake through melanocortin receptors
(Figure 1C), we investigated the effect of inhibition of hypotha-
lamic Sirt1 in POMC and AgRP expression. ICV infusion of
EX527 to fasted rats resulted in an increased POMC (Figure 3A)
and a decreased AgRP mRNA levels (Figure 3B). We next wanted
to determine if the changes seen in POMC mRNA were also
reflected at the POMC processing products level. With the
antibodies we used (see experimental procedures), the ,31 kDa
POMC precursor normally present in the ARC was undetectable
by the western blot analysis probably due to a fast processing and
low protein content of this precursor [24], (see Figure S3A), a
phenomenon commonly seen for proneuropeptide precursors.
However, we detected the 21 kDa proACTH intermediate form
Figure 2. Hypothalamic Sirt1 expression and activity are nutrient sensitive. (A) 24 hr fasting increases hypothalamic nuclear Sirt1 protein
levels. n=4. (B) Fasting increases NAD+ levels as well as the NAD+/NADH ratio in the ARC. Of note, POMC-derived peptide a-MSH level decreases by
fasting in the ARC (Figure S2C). The experiment was done twice using 3 rats per group. Values are the mean6SEM. *, vs. fed.
doi:10.1371/journal.pone.0008322.g002
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was knocked-down by siRNA infusion (Figure S1E). In support of
these in vivo studies, we also analyzed the effect of Sirt1 expression
on POMC in primary hypothalamic cultures obtained from E17.5
rat embryo diencephalons [21,25]. These cultures contain POMC
neurons, and secrete a-MSH into the media. When the Sirt1
expression was knocked down by a Sirt1 shRNA adenovirus
(Figure S3B), the a-MSH peptide in the culture media increased
(Figure S3C) as analyzed by a specific RIA.
Sirt1 Regulates POMC Expression In Vitro
To study the regulation of POMC expression by Sirt1, we used
the AtT20 cell line that has been shown to be a useful in vitro model
for this type of studies [26,27]. AtT20 cells express Sirt1 (Figure
S1B), POMC, and several key transcription factors involved in
POMC regulation such as Stat3 and FoxO1 (data not shown). The
corticotropic AtT20 cells process POMC to generate ACTH, but
does not generate a-MSH because they lack the prohormone
convertase 2 (PC2) essential for the conversion of ACTH to a-MSH
[20] (Figure S3A). Treatment of AtT20 cells with the Sirt1
activating compound resveratrol resulted in decreased POMC
protein levels (Figure 3D, left) and decreased ACTH secreted into
the media (Figure S3D). The effect of resveratrol was Sirt1 specific
because the siRNA mediated knock-down of Sirt1 blunted the effect
of resveratrol on POMC (Figure 3D, right). In addition, SA3
induced a more potent decrease in ACTH secretion (Figure S3D).
Finally,stimulationofAtT20cellswithresveratrol orSA3decreased
the POMC mRNA levels (Figure 3E) in a similar fashion to that
observed in ACTH secretion. Altogether, the in vivo combined with
the in vitro results strongly supports an inhibitory role for Sirt1 on
POMC gene regulation in a pre-translational manner.
Forkhead Transcription Factor FoxO1 Mediates Sirt1’s
Effect on POMC
The transcription factors Stat3 and FoxO1 (Figure S4A) are
involved in the regulation of POMC gene expression, and both
were shown to functionally interact with Sirt1 [28,29]. Their
acetylation states contribute to their function and/or DNA
binding [29,30]. Therefore we analyzed whether FoxO1 or Stat3
acetylation was nutrient sensitive in the ARC. Figure 4A shows
that whereas Stat3 acetylation did not change upon fasting, there
was a significant decrease in FoxO1 acetylation. Under our
experimental conditions, leptin (intraperitoneally) did not change
the acetylation state of either protein, suggesting that the fasting
induced decrease in FoxO1 acetylation was leptin-independent.
Of note, leptin did not change the ARC Sirt1 protein level (data
not shown). Blocking hypothalamic Sirt1 activity (Figure S4B)
reversed the decrease in FoxO1 acetylation, suggesting that fasting
induced deacetylation of FoxO1 required Sirt1 (Figure 4B).
Fasting induced decrease in p53 acetylation [10] was also reversed
by inhibition of Sirt1 function, and Stat3 acetylation was
insensitive to Sirt1 inhibition (data not shown). We next tested
whether Sirt1 alters FoxO1 activity. For this purpose we used an
assay that indirectly measures the amount of FoxO1 bound to a
forkhead box DNA element immobilized in a 96-well plate.
Inhibition of hypothalamic Sirt1 resulted in decreased binding of
FoxO1 (Figure 4C). We also treated N43 immortalized hypotha-
lamic cell line [31] with the Sirt1 activator SA3, which was
Figure 3. Sirt1 regulates central melanocortin system. (A) Inhibition of hypothalamic Sirt1 increases ARC POMC expression of fasted rats. n=5.
(B) ARC Agrp expression of animals in (A). n=5. (C) ProACTH increases upon Sirt1 knock-down in the ARC. Intra-ARC siRNA infused rats were
decapitated at postinjection day 2, and ARCs were analyzed by western blotting using an antibody that recognized POMC, as well as proACTH (21
kDa). Bottom graph shows the quantification of the band intensities. Values are normalized to b-actin. n=5. (D) Resveratrol decreases POMC
expression in AtT20 cells in a Sirt1- and dose-dependent manner. The experiments were done twice with n=3 per group. #,p ,0.05 vs. 5 mM
resveratrol group. (Resv= resveratrol). (E) Resveratrol (50 mM) or SA3 (50 mM) treatment of AtT20 cells decreases POMC mRNA levels detected by real
time RT-PCR. The experiment is done twice, in triplicate. #,p ,0.05 vs. resveratrol group. *, vs. DMSO or Ctrl groups.
doi:10.1371/journal.pone.0008322.g003
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FoxO1 suppresses POMC transcription [26,27], we tested whether
FoxO1 was necessary for the regulation of POMC by Sirt1.
Therefore, we knocked-down either Sirt1 or FoxO1 in AtT20 cells
followed by a treatment with SA3. As expected, ACTH secretion
was decreased upon SA3 treatment of the negative control siRNA-
transfected cells (Figure 4E). In the absence of SA3, siSirt1, or
siFoxO1 did not lead to significant changes in POMC expression
in this cell line, probably because of the basal level of POMC
expression is not inhibited by FoxO1 under the culture conditions
used. As shown for resveratrol in Figure 3D, the SA3-induced
decrease in ACTH was Sirt1 dependent, since knock-down of
Sirt1 abolished this effect (Figure 4E). Importantly, in the presence
of intact Sirt1, knock-down of FoxO1 was able to reverse the
Figure 4. FoxO1 deacetylation couples Sirt1 action to POMC expression. (A) Representative western blots showing the acetylation status of
FoxO1 andStat3 upon fasting and intraperitoneal leptin administration. 5 animals per group were evaluated. (B) Fasting induced FoxO1 deacetylation is
Sirt1 dependent. Rats were icv treated with DMSO (fed andfasted groups)or EX-527as in Figure 1D. ARCs were analyzed for the expression of Ac-FoxO1
andtotal FoxO1 by western blotting. 5 animals pergroup were evaluated. (C) Inhibition of Sirt1 activity decreases FoxO1 activity in vivo.( D) Activation of
Sirt1 in hypothalamic N43 cell line increases FoxO1 activity. (E) FoxO1 knock-down abrogates the inhibitory effect of Sirt1 on POMC expression. AtT20
cells were transfected with the corresponding siRNAs as described in Figure 3D. 24 hr after transfection the cells were serum starved and treated either
with DMSO or SA3 (5 mM) for 6 hours. ACTH in the media was measured by RIA. (F) Hypothalamic knock-down of FoxO1 reverses the affect of Sirt1
inhibition on POMC (*, vs. siControl DMSO group). Values are the mean6SEM. *, vs. respective control groups unless stated otherwise.
doi:10.1371/journal.pone.0008322.g004
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knock-down of hypothalamic FoxO1 expression (Figure S4C)
reversed the EX527-induced increase in POMC expression
(Figure 4F) as well as the EX527-induced decrease in the AgRP
expression (data not shown).
Hypothalamic Sirt1 Regulates S6 Kinase (S6K) Pathway
It has been recently demonstrated that the hypothalamic
mTOR/S6K pathway negatively regulates energy balance under
nutritional and hormonal regulation [12,32], and Sirt1 or its
activator resveratrol were suggested to repress S6K signaling
[33,34]. Therefore we asked whether the metabolic action of
hypothalamic Sirt1 also involves S6K signaling. Activation of Sirt1
in N43 cells, by either resveratrol or SA3 resulted in a decrease in
the phosphorylation of S6K and its downstream substrates
(Figure 5A, Figure 5B, Figure S5 top panels), suggesting that
Sirt1 inhibits this pathway in the mTOR signaling. Since fasting
was reported to modulate hypothalamic S6K activity, we further
Figure 5. Hypothalamic Sirt1 regulates S6K signaling. (A–B). N43 cells were serum starved overnight the day before the SA3 or Resveratrol
(50 mM each, 6 hours) treatment. 6 hr post treatment, expression level of the proteins was determined by western blotting. (C) Inhibition of
hypothalamic Sirt1 reverses the fasting induced downregulation of mTOR signaling. 300 g lean, cannulated rats either ad libitum fed (icv infused with
DMSO) or fasted (icv infused with DMSO or EX527 once at 40 hr and once 48 hr. Animals were sacrificed 1 hr post last infusion, and a western blot
was run from ARC lysates.
doi:10.1371/journal.pone.0008322.g005
Hypothalamic Sirt1
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involved in this regulation. As shown in Figure 5C (Figure S5
bottom panels), inhibition of the hypothalamic Sirt1 activity
reversed the fasting-induced decrease in S6K signaling.
Discussion
In this study, we present data supporting the hypothesis that
fasting induced hyperphagia requires hypothalamic Sirt1 activity.
This conclusion is consistent with the observation that Sirt1
protein levels and activity were increasing in fasted mouse [10]
and rat hypothalamus. Several lines of evidence in our study
demonstrate that the hypothalamic action of Sirt1 is to regulate
food intake and body weight. First, the EX527 treated rats had
decreased food intake and body weight gain. These animals’
weight gain was less than their pair-fed counterparts suggesting
that the decreased in weight gain was not exclusively due to the
reduced food intake. Second, Sirt1 showed to regulate the
expression of AgRP and POMC. The POMC derived peptide
a-MSH decreases food intake, and promotes energy expenditure
through melanocortin receptors [35] and activation of HPT axis
[21]. AgRP, on the other hand, is a strong antagonist of the
melanocortin receptors, and blocks a-MSH action. Blocking the
melanocortin receptors consistently abolished the decreased food
intake and body weight gain in hypothalamic Sirt1 inhibited
animals, showing that melanocortin receptors mediate the effect of
Sirt1 on energy balance. Third, inhibition of hypothalamic Sirt1
resulted in increased levels of serum thyroid hormones, which are
strong stimulators of basic metabolic rate and thermogenesis.
In the present work, we studied the acetylation and/or activity
of two of the transcriptional regulators of POMC: Stat3 and
FoxO1, both of which are shown to be Sirt1 substrates [28,29].
Stat3 acetylation triggers its dimerization, DNA binding and thus
transcriptional regulation [30]. Since Stat3 is a positive regulator
of POMC transcription, a potential deacetylation of Stat3 by Sirt1
might render Stat3 inactive, leading to POMC downregulation.
On the other hand, FoxO1 is a negative regulator of POMC
[26,27]. Deacetylation of FoxO1 by Sirt1 was shown to stimulate
its DNA binding, and transcriptional activity [2,29,36]. Under our
experimental conditions we could not detect any significant
change in the acetylation of ARC Stat3 by fasting, inhibition of
Sirt1, or leptin administration, working against the hypothesis that
Sirt1 targets Stat3 in the hypothalamus. However, upon fasting,
ARC FoxO1 acetylation decreases in a Sirt1 dependent manner
(Figure 4B), and Sirt1 cofactor NAD
+ and Sirt1 protein levels
increase (Figure 2), accounting for the increased Sirt1 activity
(Figure 4A, B). Also, the fasting induced decrease in POMC
expression and increase in AgRP expression were sensitive to Sirt1
enzymatic activity (Figure 3A, B). Therefore we propose that by
regulating melanocortin signaling, Sirt1 links nutrient availability
to energy homeostasis at the hypothalamic level (Figure 6). This
effect is mediated, at least in part, by the fasting induced and Sirt1
mediated deacetylation of FoxO1, such that Sirt1 shifts FoxO1’s
activity to resist the stress of fasting.
It was recently reported that Sirt1 and AMPK could activate
each other [37,38,39]. If such an interaction is true in
hypothalamic neurons as well, then AMPK might be mediating
some of the effects of hypothalamic Sirt1 on energy balance.
Randy Seeley’s group recently challenged this possibility where
they showed that central administration of resveratrol stimulated
food intake in rats (Li et al., Resveratrol Regulates Food Intake
and Glucose Homeostasis in the CNS, Endocrine Society’s 91
st
Annual Meeting, Washington D.C. [P1-379]). They proposed that
resveratrol induced food intake by activating AMPK via Sirt1
activation in the hypothalamus. Therefore, it is very likely that
Sirt1 mediated regulation of food intake involves multiple
pathways, and includes other metabolic sensors such as AMPK,
or mTOR. Our results on the regulation of S6K signaling by Sirt1
are of particular importance. Activation of hypothalamic mTOR
or increased expression of S6K in the mediobasal hypothalamus
results in decreased feeding [12,32]; therefore, Sirt1 down-
regulating S6K signaling fits our model on the regulation of
energy balance by hypothalamic Sirt1. Fasting induced down-
regulation of hypothalamic S6K signaling is reversed by leptin as
well as by inhibition of Sirt1. The exact molecular mechanism of
either regulation is not known yet. Leptin and Sirt1 might be
following independent pathways to ultimately regulate S6K
signaling. Alternatively, Sirt1 and leptin action might regulate a
common mediator of energy balance, such as AMPK [40], which
might then activate or inhibit the mTOR signaling according to
the specific input. Future research will help to identify the complex
regulation of metabolic sensors by hormonal signals for the
ultimate regulation of energy homeostasis.
Inactivation of hypothalamic Sirt1 resulting in an anorectic
phenotype might seem contradictory to some previous findings
on Sirt1. For example, mice whose food was supplement-
ed with resveratrol did not eat more than their control
counterparts [41]. However, it is not known whether
resveratrol taken orally will effectively reach all arcuate
neurons. Resveratrol is also an activator of AMPK [42], which
at the central level positively regulates food intake and body
weight gain. However, resveratrol fed mice did not show
increased food intake or body weight gain [41]. It is therefore
very likely that the peripheral effects of resveratrol might
compensate for the responses induced at the central level.
Recently Ramadori et. al. reported that chronic central
infusion of resveratrol did not alter food intake or AMPK
activity [43]. While the latter result conflicts with previous
findings on resveratrol and AMPK [42], our results from
Figure 6. Model depicting Sirt1 action in the hypothalamus.
Insulin and leptin activate PI3K, which in turn negatively regulates
FoxO1 by phosphorylation. Whether insulin and/or nutrients have direct
effects on hypothalamic Sirt1 signaling is unknown. Fasting increases
Sirt1 protein level and NAD+ levels, which results in increased Sirt1
deacetylase activity. Sirt1 deacetylates and activates FoxO1, and
regulates POMC and Agrp expressions. Hypothalamic Sirt1 action also
involves S6K signaling. Whether Sirt1 acts upstream of down-stream of
mTOR remains to be established.
doi:10.1371/journal.pone.0008322.g006
Hypothalamic Sirt1
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that the SA3 induced food intake is a short term response. It is
possible that the acute (as reported here) versus chronic actions
of hypothalamic Sirt1 might be different. Sirt1 overexpressing
mice have been generated and their physiology has been
examined. Although one study showed that Sirt1 overexpress-
ing mice ate less than wild type animals [44], two other studies
reported these mice being hyperphagic [45,46]. Whether the
observed effects of Sirt1 over expression on food intake involve
the hypothalamic Sirt1 action remains to be determined. In
summary, our study establishes a physiological role for
hypothalamic Sirt1. We propose that Sirt1 at the central level
senses the nutritional status of the body and regulates
hypothalamic central melanocortin signaling and S6K path-
way to govern food intake and body weight (Figure 6). Given
the role of Sirt1 in several peripheral tissues and hypothala-
mus, therapies centered on Sirt1 present promising results for
the treatment of metabolic diseases such as obesity.
Materials and Methods
Reagents and Antibodies
Resveratrol and Trichostatin A were purchased from Calbio-
chem (La Jolla, CA). EX-527 (6-Chloro-2,3,4,9-tetrahydro-1H-
carbazole-1-carboxamide) was from Alexis Biochemicals (San
Diego, CA). Sirt1 Activator 3 (SA3) was from Cayman Chemical
(Ann Arbor, MI). Sirt1 antibody was from Upstate (Anti-Sir2,
Lake Placid, NY). ACTH/CLIP antibody used in western blots to
detect POMC or 21 kDa ACTH precursor was from Santa Cruz
(Santa Cruz, CA). anti-aMSH antibody and the anti-ACTH
antibody (used in RIA) were developed in our laboratory and fully
described earlier [24]. Other reagents were mentioned throughout
the text.
Cell Culture
The mouse corticotropic tumoral cell line AtT20 was cultured
in DMEM (Invitrogen, Carlsbad, California) with 10% FBS. The
cells were serum starved overnight the day before resveratrol (5 or
50 mM) treatments. For fold stimulation analysis, cells were
incubated with serum free media for 5 hours, and media were
collected. Then equal amounts of resveratrol or SA3 were added
to the same dishes in a serum free media. The media were again
collected after 5 hours, speed vacuumed overnight, and analyzed
for ACTH and TRH peptides by radioimmunoassay (RIA). The
fold stimulation is simply represented by the ratio of the amount of
peptide in the second media over the amount in the first media
from the same dish. To knock-down Sirt1 or FoxO1 in AtT20s,
specific siRNAs (Invitrogen) were mixed with Lipofectamine 2000
(Invitrogen, Carlsbad, California) diluted in DMEM. The siRNA-
Lipofecetamine mixture was added onto the cells. The medium
was changed 5 hours post-transfection. The resveratrol treatment
was done 60 hours post transfection. Cells were lysed in RIPA
buffer (50 mM Tris-HCl, pH: 7.4, 150 mM NaCl, 100 mM NaF,
1 mM EDTA, 0.5% Sodium Deoxycholate, 0.1% SDS, 1% NP-
40) supplemented with protease and phosphatase inhibitor
cocktails. Sirt1, POMC, FoxO1, and b-Actin levels were analyzed
by western blot. The hypothalamic cultures were prepared as
previously described [21,25]. Briefly, the diencephalons were
excised from rat fetuses on day 17 of gestation. After enzymatic
treatment with trypsin and DNase I to dissociate the dienceph-
alons into single cells, cells were plated onto six-well dishes coated
with poly-D-lysine. To prevent glial cell growth, cytosine arabinose
(Sigma-Aldrich, St Louis, MO) was added on day 4 of the culture.
The culture was kept for two weeks before any treatment was
done, with half of the culture media being replaced with fresh
media every fourth day.
Animal Studies and ICV Infusions
Male Sprague Dawley rats were obtained from Charles River
Laboratories, Inc. (Wilmington, MA). The Institutional Animal
Care and Use Committee of Rhode Island Hospital/Brown
University approved the experimental protocols and euthanasia
procedures. Animals had free access to water all the time, and fed
ad libitum a regular diet (Purina Lab Chow #5001, Ralston Purina
Corp, St. Louis, MO) except when indicated in the experiments.
Animals were kept at a 12 hours dark/light cycle, light being off
between 18:00 and 06:00. For the intra-cerebro-ventricular (ICV)
infusion experiments, 275–300 gr rats were stereotaxically im-
planted with an intra-cerebro-ventricular (ICV) cannula (Plastic
One, VA) 10 days before the experiment. The placement
coordinates for the lateral ventricle were: anteroposterior:20.8
mm, lateral:22.0 mm, and ventral:23.6 mm from bregma. The
correct placement of the cannulas was verified by measurement of
water intake in response to ICV injection of Angiotensin II (40 ng/
rat). Rats were sacrificed by decapitation, brains were immediately
removed, and ARCs were excised between the rostral and caudal
limits of the ME and 0.5 mm to each lateral side of the ME. The
depth of each section isolated was 1 mm thick, in parallel to the
base of the hypothalamus. ARCs were processed accordingly.
Leptin was administered when indicated intra-peritoneally at a
dose of 1 mg per gram rat. Animals were sacrificed 3 hours
afterward.
Food Intake Study
Individually caged cannulated fasted rats with body weight and
age-matched were treated as follow:
EX-527 (5 mg) in 2 mL DMSO + 4 mL artificial cerebrospinal
fluid (aCSF),
SA3 (3 mg) in 2 mL DMSO + 4 mL artificial cerebrospinal fluid
(aCSF),
SA3 (3 mg) + EX-527 (5 mg) in 2 mL DMSO + 4 mL artificial
cerebrospinal fluid
1 mg SHU9119 (in 1 mL aCSF) + 2 mL DMSO + 3 mL aCSF,
1 mg SHU9119 + 5 mg EX-527 in 2 mL DMSO + 3 mL aCSF,
2 mL DMSO + 4 mL aCSF
Treatments were performed once in the morning (6 mLa t4 0h r
fasting for Figure 1A, and at 16 hr for Figure S1D), and once one
hour before the dark cycle (6 mL at 48 hr fasting for Figure 1A,
and at 24 hr for Figure S1D). The food was returned to the cages
right before dark cycle. The body weight was measured at the time
of second ICV injection (48 hr fasting for Figure 1A, and at 24 hr
for Figure S1D) and after 16 hours. Food intake was measured in
the morning when animals were weighed. The average amount of
food eaten by EX-527 group was given to the pair fed group
treated with DMSO+aCSF solution. The pair-fed group animals
consumed all the food overnight. Of note, DMSO alone did not
change food intake compared to aCSF alone (data not shown). For
the SA3 ICV experiments, 36 hour fasted and cannulated rats
were re-fed for 3 hours. At the end of re-feeding (during the light
phase), 6 mg SA3 (in DMSO) or just DMSO (4 mL) was infused
into the lateral ventricle. The food intake was measured at the
indicated time points in Figure 1A. The experiment was repeated
in O/N fasted + 3 hr re-fed rats, where the results were the same
as the presented results in Figure 1A right panel (data not shown).
For the knock-down experiments, rats under anesthesia were
placed double cannulas into the ARC. The placement coordinates
for the ARC were: anteroposterior:22.6 mm, lateral:20.5 mm,
and ventral:29.0 mm. Injector cannulas were designed to have a
Hypothalamic Sirt1
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actual ventral coordinate of injection was 29.5 mm. siRNAs to be
injected were prepared according to the in vivo siRNA
transfection protocol for brain delivery from PolyPlus Transfection
(New York, NY) [47,48,49,50]. Briefly, 5 mL DOPE (1,2-Dioleoyl-
sn-glycero-3-phosphoethanolamine, Sigma-Aldrich, St Louis,
MO) dissolved in chloroform and ethanol (final concentration
80 mM) was mixed with 20 mL jetSI
TM (10 mM from PolyPlus
Transfection, New York, NY) to form Solution A. Solution A was
diluted first with ethanol (Solution B) and then with 25% glucose
in order to obtain the solution C with a final glucose concentration
of 5%. 5,6 mg negative control siRNA (Qiagen, Valencia, CA) or
siRNA targeting rat Sirt1 (Dharmacon, Inc., Lafayette, CO) were
diluted into a final glucose concentration of 5%. Solution C was
added into the siRNA solution in a 1:1 (v/v) ratio. After 30 min
incubation at room temperature and in less than one hour, 1 mLo f
the siRNA complexes were injected into each side of the third
ventricle into the ARC of rats under anesthesia. The animals were
individually caged, and food intake and body weight were
measured every day. 2, 5 or 10 days after the injection some
animals were sacrificed and the ARC Sirt1 protein levels were
determined by western blotting. Knock down efficiency was
similar at the days analyzed. FoxO1 siRNAs were prepared
similarly. 4 mL was injected ICV at 08:00hr and 16:00hr every day
for 4 days. The rats were fasted the last 24 hours for the EX527
infusions, which were done once at the beginning of fasting and
another time in the following morning. Rats were sacrificed after
25 hours of fasting.
Western Blotting
Ad libitum fed or fasted rats were sacrificed by decapitation and
the brains were immediately removed. ARC and PVN were
excised, and lysed in RIPA buffer containing a mixture of protease
and phosphatase inhibitors (Sigma-Aldrich, St Louis, MO)
supplemented with 10 mM Nicotinamide, 10 mM Trichostatin
A, and 10 mM EX527. Protein quantification was done by
Bradford assay. The Precision Plus Protein standards were used as
molecular mass markers (Bio-Rad Laboratories, Richmond, CA).
After separation on SDS PAGE, the proteins were transferred to
PVDF membranes, and blocked with 5% dry milk (5% BSA was
used for the phosphorylated proteins) in TBS with 0.1% Tween-20
(TBS/T). For Sirt1 analysis, the membranes were cut into two
from 75 kDa marker line and lower parts were incubated with
mouse anti-beta-Actin antibody (Santa Cruz, 1:10000), top parts
were incubated with rabbit anti-Sirt1 antibody (Upstate, 1:1500).
Figure S1E serves as a control that this antibody can be used to
detect rat ARC Sirt1 by western blotting. For detection of
acetylated p53 (1:500, Cell Signaling), acetylated FoxO1 (1:200,
Santa Cruz), acetylated Stat3 (1:500, Cell Signaling), and
phospho-Stat3 (1:1000) the blots were incubated with the
modification specific antibodies, and developed, followed by b-
mercaptoethanol stripping, and incubation with the total p53
(1:200, Santa Cruz), FoxO1 (1:1000, Cell Signaling), Stat3 (1:200,
Santa Cruz) antibodies for evaluation of equal protein loading.
HRP conjugated goat anti-mouse, goat anti-rabbit, and rabbit
anti-goat secondary antibodies (Bio-Rad Laboratories, Richmond,
CA) were used for detection of the protein bands. All primary
antibody incubations were done at 4uC overnight, except for the
acetylated-Stat3 antibody, where the incubation was for 48 hours
at 4uC. Secondary antibody incubations were done at room
temperature in 5% non-fat dry milk in TBS/T for 1 hour (2 hour
for the acetylated Stat3 antibody). Band intensities were quantified
by NIH Image J software.
Adenoviral Infection
Control shRNA and Sirt1 shRNA adenoviruses were kindly
provided by Dr. Pere Puigserver (Dana-Farber Cancer Institute,
Department of Cell Biology, Harvard Medical School, MA, USA).
For the infection of hypothalamic cultures 1,5610
7 infectious
particles (per well) were added into the media of six well dishes at
day 14 of the culture. 4–5 days later, cells were added fresh media
with 0.1% BSA and 0.1% FBS. The media was collected 6 hours
later for the a-MSH RIA. Cells were lysed in RIPA buffer; protein
content was determined by Bradford assay. Ten mg of protein was
run on SDS-PAGE to assess the Sirt1 knock-down efficiency.
Double Immuno-Histochemistry (IHC) for Sirt1 and ACTH
Rats were anesthetized with pentabarbitol and systemically
perfused with 4% paraformaldehyde solution. Brains were
removed and further fixed for 2 hours, and then kept in 20%
sucrose solution at 4uC overnight. Frozen brains were cut in 25-
mm-thick coronal sections on a sliding cryostat. Tissue samples
were pretreated with 1% NaOH and 1% H2O2 in H2O for 20
minutes, 0.3% glycine for 10 minutes, and 0.03% SDS for 10
minutes. After that, sections were blocked for 1 hour with 3%
normal goat serum in PBS/0.25% TritonX-100/0.2% sodium
azide. The anti-Sirt1 antibody in blocking solution was then added
(1:1,000) and incubated overnight at 4uC. On the next day,
sections were washed, incubated with biotinylated secondary goat
anti-rabbit antibody for 2 hours (1:1,000), and then treated with
avidin biotin complex solution for 1 hour. Finally, the signal was
developed with diaminobenzidine solution, giving a brown
precipitate. Consecutively, IHC for ACTH was performed by
incubation overnight at 4uC with the primary antibody (1:2,000) in
blocking solution. On the next day, sections were washed,
incubated with a fluorescent secondary goat anti-rabbit Alexa
596 (red) antibody for 1 hour. Results were visualized using either
fluorescence (ACTH) or bright-field light (Sirt1) sources. Fluores-
cent images (12 bit) and DAB images (24 bit) were acquired with a
Nikon E800 microscope (Nikon Inc. Melville NY) and a Spot II
digital camera (Diagnostic Instruments, Sterling Heights MI).
Using ImageJ (NIH, Springfield, VA) and Adobe Photoshop
(Adobe, San Jose, CA) fluorescence and bright-field photographs
were combined using RGB channels to visualize double-labeled
cells.
Radioimmunoassay Analysis (RIA)
The assays used for a-MSH and ACTH-derived peptides were
previously developed in our laboratory [24]. Primary antibodies
were also developed in our laboratory. Each peptide was iodinated
with 125I using the chloramine T oxidation-reduction method
followed by HPLC separation, and the purified peptide was used
as the tracer. The a-MSH RIA assay was performed in 0.5 ml of
phosphate buffer (pH 7.4)/500 mg/l sodium azide-2.5 g/l BSA,
with primary anti-a-MSH antiserum (1:20,000) and 5,000 cpm of
125I-desacetyl a-MSH tracer. The a-MSH assay used under these
experimental conditions detected 100% of acetyl and desacetyl a-
MSH of the amidated forms. The a-MSH assay has no cross-
reactivity with CLIP [24]. The ACTH RIA assay was performed
in 0.5 ml of RIA buffer containing anti-ACTH antiserum
(1:30,000) and 5,000 cpm of 125I-ACTH tracer. The ACTH
assay used under these experimental conditions can detect 100%
of CLIP and ACTH forms; however, this assay does not cross-
react with any form of a-MSH. The RIA kits from MP
Biomedicals Diagnostic Division (Orangeburg, NY) were used to
measure serum T3 and T4 levels. Similar results were obtained
when the experiment was done on 24 hour-fasted rats (data not
shown) as opposed to 48 hour-fasted rats (Figure 1D). For the
Hypothalamic Sirt1
PLoS ONE | www.plosone.org 9 December 2009 | Volume 4 | Issue 12 | e8322detection of ARC a-MSH, fed or fasted extracted rat ARCs were
boiled in 2N acetic acid supplemented with protease inhibitors,
and then sonicated. After centrifugation, protein/peptide concen-
tration was determined by Bradford assay. Equal amounts of total
protein were speed vacuumed for a-MSH RIA.
Real Time RT-PCR
Cannulated rats fasted for 25 hours were infused with DMSO
(control group) or EX-527 once at the beginning of the fasting
period and a second time in the following morning (16 hr of
fasting). Rats were sacrificed after 25 hours of fasting. Brains were
immediately removed, and ARCs were excised. Total RNA (1 mg)
isolated (Trizol Reagent, Invitrogen) from fresh arcuate nucleus
tissue was converted to cDNA and used to screen expression levels
of Sirt1, POMC, AgRP, and tubulin (internal control). Reactions
were amplified in an ABI Prism 7500 FAST sequence detector
(Applied Biosystems) and acquired data were analyzed using the
DDCt method to determine the expression level of each transcript
normalized to the expression level of the housekeeping gene
(tubulin). RNA from AtT20s was isolated with Trizol and the
described protocol is followed. The primer sequences used for real
time PCR are available upon request.
NAD
+- NADH Measurements
NAD
+-NADH measurements were done using BioVision
(Mountain View, CA) NAD+/NADH Quantification kit accord-
ing to the manufactures instructions. Briefly, ARCs were sonicated
in the NADH/NAD extraction buffer. Samples were filtered
through 10kDa molecular weight cut off filters (Millipore). Half of
the eluate was used to determine NAD total (NADt=NADH +
NAD
+). The other half was heated to 60uC for 30 minute, and
used for NADH measurements. NAD
+ was simply calculated by
NAD
+=NADt-NADH. The reactions were prepared in 96 well
dishes, and read at OD450. The concentrations were determined
after applying the reading to the linear part of the standard curve
generated by the NADH standard supplied.
FKHR Transcription Factor Assay
N43 or hypothalamic nuclear isolation was done using
Nuclear Extract Kit (Active Motif, CA). Nuclear lysates were
used without freeze-thaw cycles for FoxO1 activity assay using
FKHR Transcription Factor Assay kit according to manufac-
turer’s instructions. Briefly, nuclear lysates were added into the
provided 96-well plate. After 1 hr incubation at room
temperature, the wells were washed, and subsequently
incubated with the primary and, HRP-conjugated secondary
antibodies. The color development was carried out for 6–7
minutes. The OD450 was normalized to the total nuclear
lysate added per well. Each sample was run in triplicate per
assay. The detected signal’s specificity was confirmed by
addition of wt vs. mutated oligonucleotides provided with the
kit, such that the signals were reversed by the addition of wt
but not mutant oligonucleotides (data not shown).
Statistical Analysis
Results were expressed as average 6 SEM, (n is given in the
Figure legends). Statistical significance of differences was calculat-
ed with Student’s t test.
Supporting Information
Figure S1 A-G. Sirt1 is expressed in the rat hypothalamus, and
modulation of its activity or expression alters food intake. (A)
Coronal brain sections of an ad libitum fed rat subjected to IHC
(immunohistochemical staining) using an antibody against Sirt1.
Sirt1 is expressed in the nuclei of the hypothalamus involved in
energy homeostasis: (Left) paraventricular nucleus (PVN), (Middle)
arcuate nucleus (ARC) and Median Eminence (ME), (Right) ARC
in higher magnification. 3 rats were examined for their
hypothalamic Sirt1 expression pattern. (3V: Third Ventricle,
FX: Fornix, OPT: Optic Tract)). (B) (Left) Analysis of Sirt1
expression by western blotting. Sirt1 is present in the ARC, PVN,
primary hypothalamic cultures obtained from rat embryo
diencephalons (Hyps), and the AtT20 cell line. An equal amount
of protein (20 mg) was run on SDS-PAGE for the western blot.
(Right) Whole hypothalamic lysate (20 mg) was run on an 8% gel,
and a western for Sirt1 was done. (C) Light micrographs showing
the immunohistochemical (DAB staining) distribution of Sirt1 in
hippocampus (left) or cortex (right). (D) (Left and middle panels)
Food intake and body weight gain of 24 hr fasted rats, which were
DMSO or EX527 infused at 16 hr and 24 hr of fasting. Food
intake and body weight gain were measured 24 hours after the last
infusion, at which point the food was added into the cages. (Right
panel) Hypothalamic acetylated-p53 level decreases after central
infusion of SA3. (E) (Left) Knock-down of Sirt1 expression by
intra-ARC siRNA infusions. Top panel shows western blots for
Sirt1 using the ARC samples obtained 48 hr after siRNA infusion.
b-actin is used as the loading control. Bottom graph shows the
quantification of the western blot on top. ARC Sirt1 protein levels
decreases around 40% upon siRNA infusion. Values are
normalized to b-actin levels. n=4 per group. (Right) ARC Sirt1
protein levels 5 days post-injection. At 10 days post-injection (data
not shown), Sirt1 protein levels were very similar to 5 days post-
injection. (F) Sirt1 staining pattern changes upon Sirt1 knock-
down only in the ARC. Sirt1 IHC after infusion of (-) ctrl siRNA
(right side of 3V) or Sirt1 siRNA (left side of 3V) into the ARC.
Top panel ARC, bottom PVN. (G) Quantification of the Sirt1
positive nuclei in either side of the ARC from (B). 4 animals per
group and 6 sections per animal were analyzed. *, p,0.05 vs. (-)
Ctrl siRNA. Values are the mean 6 SEM. 3V, third ventricle.
*, p,0.05 vs. Ctrl.
Found at: doi:10.1371/journal.pone.0008322.s001 (10.28 MB
TIF)
Figure S2 A-C. Sirt1 is expressed in POMC neurons. (A) IHC
with ACTH antibody to stain POMC neurons in the ARC. (B)
Immunohistochemical staining for Sirt1 and POMC in the ARC.
Top row shows lower magnification IHC for Sirt1 and POMC in
coronal rat brain sections of ARC. All POMC neurons express
Sirt1. Bottom row shows higher magnification images of the top
panels. (C) a-MSH level decreases in the 48-hour fasted rat ARC
compared to the fed animals. n=5. Values are the mean 6 SEM.
*, p,0.05 vs. fed.
Found at: doi:10.1371/journal.pone.0008322.s002 (10.04 MB
TIF)
Figure S3 A-D. Sirt1 regulates POMC expression. (A) Post-
translational processing of POMC. POMC is first cleaved into two
giving rise to the 21 kDa ACTH precursor, which is then
processed into ACTH and ultimately into a-MSH in the ARC and
hypothalamic cultures. AtT20 cells process POMC up to ACTH
since they lack the enzyme PC2, which cuts ACTH to produce a-
MSH. (B) Knock-down of Sirt1 in rat primary hypothalamic
cultures (Hyps). Sirt1 shRNA Adenovirus or the negative control
shRNA adenovirus infected hypothalamic cultures were analyzed -
by western blotting- for the Sirt1 expression. n=4. (C) a-MSH
secreted from Hyps in (B) is increased upon Sirt1 knock-down. (D)
Resveratrol (50 mM) or SA3 (40 mM) treatment decreases ACTH
released into the culture media. Media were collected from the
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secreted (negative control, data not shown) from preproTRH
transfected AtT20s is not affected by the resveratrol or SA3
treatment (n=3, per condition. The experiment was done twice).
Found at: doi:10.1371/journal.pone.0008322.s003 (8.92 MB TIF)
Figure S4 A-C. Inhibition of hypothalamic Sirt1 activity, and
icv infusion of FoxO1 specific siRNAs. (A) FoxO1 western using
total rat hypothalamic lysate. (B) Elevation of the acetylated p53
levels in the hypothalamus of rats icv treated with the Sirt1
inhibitor EX527. (C) icv infusion of FoxO1 specific siRNAs results
in decreased FoxO1 protein levels.
Found at: doi:10.1371/journal.pone.0008322.s004 (10.31 MB
TIF)
Figure S5 Hypothalamic Sirt1 regulates S6K signaling. Densi-
tometry of the western blots presented in Figure 5A (top three
graph), and Figure 5C (bottom two graphs).
Found at: doi:10.1371/journal.pone.0008322.s005 (9.47 MB TIF)
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